[Hodgkin's disease: treatment of clinical stages II3+A, IB, IIB, IIIA and IIIB with short chemotherapy (3 MOPP, or 3 CVPP), splenectomy and limited irradiation. Results after 4 years of a prospective protocol including 94 patients].
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D013156:Splenectomy; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D008130:Lomustine; D011241:Prednisone
Maladie de Hodgkin: traitement des stades cliniques II3+A, IB, IIB, IIIA, IIIB, par chimiothérapie courte (3 MOPP ou 3 CVPP), splénectomie et irradiation limitée. Résultats a 4 ans d'un protocole prospectif inculant 94 patients.